Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck

Squamous cell cancer of the head and neck (SCCHN) is the sixth leading cause for cancer deaths worldwide. Despite extense knowledge of risk factors and pathogenesis about 50 percent of all patients and essentially every patient with metastatic SCCHN eventually die from this disease. We analyzed the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncotarget 2011-08, Vol.2 (8), p.599-609
Hauptverfasser:	Hoellein, Alexander, Pickhard, Anja, von Keitz, Fabienne, Schoeffmann, Stephanie, Piontek, Guido, Rudelius, Martina, Baumgart, Anja, Wagenpfeil, Stefan, Peschel, Christian, Dechow, Tobias, Bier, Henning, Keller, Ulrich
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal, Humanized Antineoplastic Agents - pharmacology Aurora Kinase A Aurora Kinase B Aurora Kinases Carcinoma, Squamous Cell - enzymology Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - surgery Cell Line, Tumor Cetuximab Disease-Free Survival Drug Resistance, Neoplasm - drug effects Female Head and Neck Neoplasms - enzymology Head and Neck Neoplasms - mortality Head and Neck Neoplasms - pathology Head and Neck Neoplasms - surgery Humans Immunohistochemistry Kaplan-Meier Estimate Male Middle Aged Molecular Targeted Therapy Prognosis Protein Kinase Inhibitors - pharmacology Protein-Serine-Threonine Kinases - antagonists & inhibitors Protein-Serine-Threonine Kinases - metabolism Receptor, Epidermal Growth Factor - antagonists & inhibitors Receptor, Epidermal Growth Factor - metabolism Research Papers Survival Rate Time Factors Up-Regulation
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!